01.12.2016 | Case report | Ausgabe 1/2016 Open Access
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2016
Wichtige Hinweise
Competing interests
DP, MD has served on Speakers’ Bureaus or received Honoraria from Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, and Bayer HealthCare.
Authors’ contributions
DP, MD provided treatment for the patient, conceived the case study, and coordinated and helped to draft the manuscript. KR, CRNP provided technical help and writing assistance. All authors read and approved the final manuscript. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Abstract
Background
We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications.
Case presentation
A 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover high-dose sildenafil in addition to ERA therapy.
Conclusion
This case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no interruption in therapy.
